Author:
Singh Tripti,Maw Thin Thin,Henry Brian L.,Pastor-Soler Núria M.,Unruh Mark L.,Hallows Kenneth R.,Nolin Thomas D.
Publisher
American Society of Nephrology (ASN)
Subject
Transplantation,Nephrology,Critical Care and Intensive Care Medicine,Epidemiology
Reference34 articles.
1. US Food and Drug Administration: FDA Drug Safety Communication: Safety Review of Post-Market Reports of Serious Bleeding Events with the Anticoagulant Pradaxa (Dabigatran Etexilate Mesylate), 2011. Available at: www.fda.gov/Drugs/DrugSafety/ucm282724.htm#sa. Accessed January 21, 2013
2. Boehringer Ingelheim Pharmaceuticals, Inc.: Pradaxa® (Dabigatran Etexilate Mesylate) Prescribing Information, 2012. Available at: www.pradaxa.com. Accessed January 21, 2013
3. Dabigatran versus Warfarin in Patients with Atrial Fibrillation
4. Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation
5. Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects
Cited by
91 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献